.Attribute Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a typical consequence of 11 months, people along with metastatic gastrointestinal tumors that acquired biomarker-matched treatments based upon spreading tumor DNA profiling revealed a greater scientific advantage than those receiving incomparable treatment.